LSCDS #ScienceNews and #Innovation

Today, in our weekly LSCDS feature #ScienceNews,  we would like to highlight this editorial on ‘Right To Shop’ Legislation in Utah that permits purchasing a 90-day supply of a prescription across the boarder:  “Americans cross border into Mexico to buy insulin at a fraction of U.S. cost”.

In industry, the spotlight is on Sanofi as the momentum seems to have returned after years of decline. Thanks to the major contribution from the eczema player Dupixent and rare disease drugs.

Lastly, Pfizer and Astellas announced a significant survival benefit of Xtandi in a phase 3 trial of men with metastatic hormone-sensitive prostate cancer, in combination with androgen deprivation therapy (ADT).

By |2019-02-13T11:18:00+00:00February 13th, 2019|Bassem Toeama, ScienceNews&Innovation|0 Comments

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.